Simvastatin induces apoptosis in PTEN-haploinsufficient lipoma cells

FRANZISKA KÄSSNER¹, TINA SAUER¹, MELANIE PENKE¹, SANDY RICHTER¹, KATHRIN LANDGRAF¹², ANTJE KÖRNER¹², WIELAND KIESS¹, NORMAN HÄNDEL¹ and ANTJE GARTEN¹³

¹University Hospital for Children and Adolescents, Center for Pediatric Research Leipzig (CPL); ²Leipzig University Medical Center, IFB Adiposity Diseases, D-04103 Leipzig, Germany; ³University of Birmingham, Institute of Metabolism and Systems Research (IMSR), Birmingham B15 2TT, UK

Received June 9, 2017; Accepted January 31, 2018

DOI: 10.3892/ijmm.2018.3568

Abstract. Adipose tissue tumors (lipomas) frequently develop in patients with heterozygous germ line phosphatase and tensin homolog (PTEN) mutations. Simvastatin has been demonstrated to exhibit antitumor effects, and so the aim of the present study was to assess the effects of simvastatin on the growth of human PTEN haploinsufficient lipoma cells. Whether the effects of simvastatin in lipomas are mediated via PTEN upregulation was also assessed. The results of the present study revealed that simvastatin treatment reduced cell viability and induced apoptosis in human lipoma cells. Furthermore, it was demonstrated that the expression of cellular PTEN mRNA and protein was increased following simvastatin stimulation. In addition, the phosphorylation of protein kinase B and downstream targets of mammalian target of rapamycin (mTOR) and 4E-binding protein (4E-BP)-1 was attenuated. It was also demonstrated that simvastatin induced PTEN transcriptional upregulation by increasing peroxisome proliferator-activated receptor (PPAR)γ expression. The small interfering RNA-mediated knockdown of PPARγ abrogated the stimulatory effect of simvastatin on the PTEN protein, but did not influence apoptosis. The results of the present study suggest that simvastatin may be beneficial for patients with inoperable PTEN haploinsufficient lipomas.

Introduction

Benign tumors of adipose tissue are often exhibited in humans with rare phosphatase and tensin homolog (PTEN) Hamartoma Tumor Syndrome (PHTS), which is caused by heterozygous germ line mutations within the tumor suppressor PTEN gene (1). Although noncancerous, these lipomas frequently develop to form extended fatty tissue tumors (lipomatosis), which may infiltrate other tissues and cause numerous side effects, including organ obstruction, resulting in loss of function and chronic pain (2). A previous study assessed a child with a severe PHTS phenotype who exhibited abdominal lipomatosis (3). It was demonstrated that an individual treatment attempt using the mammalian target of rapamycin complex (mTOR) inhibitor sirolimus led to an improvement in the patient's general condition and a decrease in thymus size; however, lipomatosis regression was not observed (3). At present, no targeted therapies for the treatment of PHTS-associated lipomatosis exist. Surgical excision of the tumor and symptomatic treatment remain the only form of therapy available (4). There is therefore an urgent need to uncover novel therapeutic approaches for patients with PHTS and non-resectable adipose tissue tumors.

Statins, also known as 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, are widely utilized to decrease serum cholesterol levels (5). Previous studies have demonstrated that statins elicit numerous non-lipid modifying effects, which have been revealed to exhibit anti-tumor effects in vitro, in vivo and in epidemiological studies (6-9). In particular, simvastatin was demonstrated to increase PTEN protein levels and activity, thus downregulating the activation of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway (10-13). Furthermore, a case report of a 54-year-old man described a dramatic reduction of an isolated subcutaneous lipoma associated with simvastatin therapy (14).

The aim of the present study was to assess the effects of simvastatin on three lipoma cell lines, termed lipoma PTEN-deficient 1-3 (LipPDI-3), established from the resected lipoma tissue of pediatric patients with heterozygous germ line...
PTEN deletion or mutations. It was hypothesized that simvastatin treatment may lead to attenuated cell growth or the induction of apoptosis in these PTEN haploinsufficient lipoma cells by increasing levels of the PTEN protein.

Materials and methods

Informed consent. Written informed consent was provided by the parents of all patients enrolled in the present study. A total of 3 patients (2 male, 1 female) and 2 healthy control patients (1 male, 1 female), aged 0-18 years were enrolled in the present study. All patients were admitted to the Hospital for Child and Adolescent Medicine (Leipzig University, Leipzig, Germany) and samples were collected between July 2007 and December 2016. Patients with morbidities other than PHTS were excluded. One patients received sirolimus following lipoma resection (3). All LipPd cells used in this study were obtained from lipomatous adipose tissue that was resected for diagnostic and therapeutic reasons. Control primary pre-adipocytes were removed from adipose tissue obtained from pediatric or young adult patients during routine surgery. Ethical approval for these studies was obtained from the Ethics Committee of the University of Leipzig (ref. no. 425-12-171220; Leipzig, Germany).

Cell lines, cell culture and treatments. Genetic analyses of PTEN revealed a heterozygous deletion affecting exons 2-9 of 9 of PTEN in LipPD1 cells (3,15). A heterozygous PTEN mutation was detected in LipPD2 (c.404T>A, p.I135K) and LipPD3 (exon 1, c.76A>C, p.T26P). A schematic presentation of the genetic changes in PTEN is presented in Fig. 1A. The following cell lines were used as PTEN wild-type controls: Simpson-Golabi-Behmel (SGBS, kindly supplied by Dr. M. Wabitsch, University Hospital, Ulm, Germany) (16,17) cells and normal primary pre-adipocytes obtained from pediatric or healthy young adult adipose tissue. All cell strains were established according to protocols as described previously (3,17). Cells were maintained in Dulbecco's Modified Eagle's medium (DMEM)/F12 medium supplemented with 10% fetal calf serum, glutamine (2 mM), biotin (33 mM) and pantothenic acid (17 mM; all from Biochrom, Ltd., Cambridge, UK) at 37˚C in a humidified atmosphere containing 5% CO₂. Cells were maintained in Dulbecco's Modified Eagle's medium (DMEM)/F12 medium supplemented with 10% fetal calf serum, glutamine (2 mM), biotin (33 mM) and pantothenic acid (17 mM; all from Biochrom, Ltd., Cambridge, UK) at 37˚C in a humidified atmosphere containing 5% CO₂.

Cell viability and apoptosis. The effect of simvastatin on proliferation was measured using a Cell Proliferation Reagent WST-1 (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer's protocol. Cells were seeded in 96-well plates at a density of 10,000 cells/cm² and incubated for 48 h with 0, 0.1, and 10 µM simvastatin. Apoptosis was determined using Annexin V-fluorescein isothiocyanate (FITC; BD PharMingen; BD Bioscience, San Jose, CA, USA)/propidium iodide (PI) staining according to manufacturer's protocol. Briefly, cells were seeded at a density of 5,000 cells/cm² and incubated for 48 h with 0, 10 µM simvastatin. Cells were trypsinized and incubated with Annexin V-FITC/PI for 10 min at 4˚C in the dark. Annexin V-FITC-positive cells represent early apoptosis and Annexin V-FITC/PI double positive cells indicate late apoptotic cells.

Reverse transcription quantitative polymerase chain reaction (RT-qPCR). For qPCR analysis mRNA was extracted from LipPD1 cells using the RNeasy mini kit (Qiagen GmbH, Hilden, Germany) according to the manufacturer's protocol. A total of 1 µg mRNA was reverse transcribed at 39˚C for 1 h into cDNA using M-MLV Reverse Transcriptase (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA). PCR reactions were performed using Taqman Mastermix FAST qPCR Master Mix Plus Low ROX (Eugentec, Liege, Belgium) or Absolute qPCR SYBR-Green Low ROX Mix (Thermo Fisher Scientific, Inc.) and the Applied Biosystems 7500 Real-Time PCR System (Applied Biosystems; Thermo Fisher Scientific, Inc.). Primers and probes were designed using the PrimerExpress software version 3.0 (Applied Biosystems; Thermo Fisher Scientific, Inc.) and sequences are presented in Table I. The following thermocycling conditions were used: Activation at 95˚C for 15 min, 40 cycles of denaturation at 95˚C for 15 sec, annealing at 60˚C for 30 sec, elongation at 72˚C for 30 sec. A standard curve of serial dilutions of plasmid DNA of the respective target gene was included on each plate. The copy number of each sample was calculated from the standard curve and normalised to the mean of the two housekeeping genes TATA box binding protein (TBP) or hypoxanthine phosphoribosyltransferase (HPRT) expression (18).

Western blot analysis. For protein analysis, cells were lysed with modified radiolymphoprecipitation assay buffer [50 mM Tris HCl; pH 7.4; 1% NP-40; 0.25% sodium deoxycholate; 1x Roche complete protease inhibitor cocktail (Roche Diagnostics GmbH); 1 mM EDTA; 1 mM sodium orthovanadate; and 1 mM sodium fluoride], protein concentrations were determined using a DC protein assay (Bio-Rad Laboratories, Inc., Hercules, CA, USA) and proteins (20 µg/lane) were separated by 10% SDS-PAGE. Following semi-dry transfer onto nitrocellulose membranes, membranes were blocked using 5% non-fat dry milk in TBS buffer containing 0.1% Tween-20 (TBST) for 1 h at room temperature. Blots were then incubated overnight at 4˚C with the appropriate primary antibody. The antibodies utilized in western blotting are summarized in Table II. Blots were washed three times for 5 min with TBST and incubated with horseradish peroxidase (HRP)-goat anti rabbit (P-0448) or HRP-goat anti mouse (P-0447) antibodies (Dako; Agilent Technologies, Inc., USA) at a dilution of 1:2,000 for 2 h at room temperature. Protein bands were detected using Luminata Classic Western horseradish peroxidase Substrate (EMD Millipore) or Amersham ECL Prime Western Blotting Detection Reagent (GE Healthcare, Chicago, IL, USA). Glyceraldehyde-3-phosphate dehydrogenase (EMD Millipore) was used as a loading control. ImageJ 1.41 was used for densitometric analysis (National Institutes of Health, Bethesda, MD, USA).

Small interfering (si)RNA-mediated knockdown of PPARγ. LipPD1 cells were microporated using the Neon Transfection System 100 µl kit (Invitrogen; Thermo Fisher Scientific, Inc.) with the PPARγ ON-TARGETplus SMARTpool siRNA
Table I. Primer and probe sequences.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Direction</th>
<th>Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>PTEN</td>
<td>Forward</td>
<td>GTTACCGGCCCTCAAT</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>CCCCCACTTTCACAGT</td>
</tr>
<tr>
<td>PPARγ</td>
<td>Forward</td>
<td>GATCCAGTTGTCAGATTACA</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>GAGGGAGTTGGAAAGCTTCTC</td>
</tr>
<tr>
<td></td>
<td>Probe</td>
<td>TGACCTGAAACTTCAAGAGTACCA AAGTGGCA</td>
</tr>
<tr>
<td>TBP</td>
<td>Forward</td>
<td>TTGAAACTTGACCTAAAGACCATTGC</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>TTCGTGGCTCTTTATCCTCATG</td>
</tr>
<tr>
<td></td>
<td>Probe</td>
<td>AACGCCGAATAATATCCAAAGCGGT TTG</td>
</tr>
<tr>
<td>HPRT</td>
<td>Forward</td>
<td>GGCAGTATAATCCAAGATGGTCA</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>GTCGCGTTATATCCCAACACTTCGT</td>
</tr>
<tr>
<td></td>
<td>Probe</td>
<td>CAAGCTTGCTGTGTAAGAACCC</td>
</tr>
</tbody>
</table>

PTEN, phosphatase and tensin homolog; PPARγ, peroxisome proliferator-activated receptor; TBP, tata box binding protein, HPRT, hypoxanthine phosphoribosyltransferase.

reagent and the respective negative control (ON-TARGETplus control pool; GE Healthcare Dharmacon, Inc., Lafayette, CO, USA) as previously described (18). A total of 10⁶ cells were transfected with siRNA at a final concentration of 500 nmol/l, seeded at a density of 10⁵ cells/well in 6 well plates and cultured for 24 h. The following day, the culture medium was replaced with serum-free DMEM for 24 h. Cells were then stimulated using simvastatin (10 µM) as above.

Statistical analysis. Data are presented as the mean ± standard error of the mean of at least three independent experiments. Significant differences were determined using GraphPad Prism 6 software (GraphPad Software, Inc., La Jolla, CA, USA) and the unpaired Student's t-test or one-way analysis of variance followed by a post hoc Bonferroni multiple comparison test. P<0.05 was considered to indicate a statistically significant difference.

Results

Decreased PTEN protein levels and enhanced AKT in PTEN deficient lipoma cells. Basal PTEN mRNA and protein levels were analyzed to assess the impact of the heterozygous PTEN deletions or mutations (Fig. 1A) on lipoma cells. Lipoma cells with a large heterozygous PTEN deletion (3) possessed a significantly lower PTEN mRNA expression compared with PTEN wild-type control pre-adipocytes (P<0.05; Fig. 1B). PTEN mRNA expression was similar in lipoma cells with PTEN point mutations and non-mutant cells (Fig. 1B). However, in all three lipoma cell cultures, PTEN protein levels were lower compared with PTEN wild-type control cells (P<0.05; Fig. 1C). It was then assessed whether reduced PTEN protein levels led to enhanced AKT phosphorylation. Mutation-positive cells exhibited significantly higher levels of phosphorylated AKT (Thr308) compared with control cells (LipPd1 and LipPd3; P<0.05) (Fig. 1D).

Simvastatin treatment induces apoptosis in lipoma cells. The effect of simvastatin on the viability of lipoma cells was determined following incubation for 24, 48 and 72 h (Fig. 2A). Simvastatin at 10 µM significantly decreased the viability of LipPd1, LipPd2 and LipPd3 cells to 67.5±8.3, 68.0±14.3 and 64.0±9.2% at 48 h and to 42.3±8.8%, 43.3±14.0% and 37.2±6.9% at 72 h incubation, (P<0.05; Fig. 2A and B). At the same dose and incubation time, simvastatin induced apoptosis by 28% in LipPd1 compared with LipPd1 cells incubated without simvastatin (Fig. 2C). Following incubation with 10 µM simvastatin, cells were equally distributed between early and late apoptotic phases. No effect on cell viability was observed following an incubation of 24 h (data not shown).

Simvastatin treatment decreases AKT/mTOR activation. Previous studies have demonstrated that simvastatin upregulates PTEN transcription (8-10), and so PTEN mRNA expression in lipoma cells was assessed following incubation with simvastatin. Stimulation with 10 µM simvastatin resulted in a significant increase in the expression of PTEN mRNA to 1.4±0.1-fold in LipPd1 compared with control cells following a 6 h incubation (P<0.05; data not shown). The effect of simvastatin on the PTEN protein and AKT/mTOR pathway activation following 6, 12, 24 and 48 h of incubation was then assessed. Simvastatin (10 µM) resulted in an increase in phosphorylated and total PTEN protein levels in LipPd1 cells when incubated for 24 h (Fig. 3A-C). In addition, a downregulation of AKT phosphorylation at T308 and S473 (Fig. 3A, D and E) was observed following 24 and 48 h incubation. The activation of mTOR, a downstream target of AKT, was then examined. The results demonstrated that 48 h incubation with 10 µM simvastatin significantly decreased mTOR1 phosphorylation at Ser2448 by 48.8±1.2% (P<0.05; Fig. 3F and G) and phosphorylation of the mTOR target 4E-binding protein-1 (4EBP-1) by 64.9±1.2% (P<0.05; Fig. 3F and H). Increased PTEN protein levels were also observed in LipPd2 and LipPd3 cells following 6 h of incubation with 10 µM simvastatin (both P<0.05; data not shown). These results indicate that simvastatin incubation affects PTEN protein levels and AKT/mTOR activation in a time-dependent manner.

PPARγ mediates simvastatin action on PTEN protein expression, but not on apoptosis. The present study aimed to identify the mediators of simvastatin. Previous studies have demonstrated that simvastatin acts through the activation of nuclear factor (NF)xB (9,13,19). However, in the present study, no significant effect on NF-xB phosphorylation was observed following incubation with simvastatin (data not shown). Additionally, no significant upregulation of the NF-xB target protein B-cell lymphoma-2 (13,20,21) was detected (data not shown). Previous studies have indicated the ability of the transcriptional regulator PPARγ to induce PTEN mRNA (22-25). The results of the present study demonstrated that a 6 h simvastatin incubation significantly upregulated LipPd1 cell PPARγ protein expression by 1.88±0.3-fold (P<0.05; Fig. 4A). It was then determined whether knockdown of PPARγ abrogated the stimulatory effect of simvastatin on PTEN levels.
siRNA-mediated knockdown of PPARγ to 34.8±1.2% was confirmed at the protein level (Fig. 4B) and this knockdown significantly attenuated the upregulation of PTEN mRNA and protein induced by simvastatin (P<0.05; Fig. 4C). These results indicate that simvastatin induces PTEN expression in a PPARγ-dependent manner in LipPd1 cells. Furthermore,
Figure 2. Simvastatin treatment decreased lipoma cell viability and induced apoptosis. LipPd1-3 cells were incubated with increasing doses of simvastatin. Cell viability was measured using a WST-1 assay following (A) 48 and (B) 72 h incubation. Data were normalized to the untreated control. (C) LipPd1 cells were stained with Annexin V/propidium iodide following 48 h incubation with simvastatin and apoptosis was assessed. Data are presented as the mean ± standard error of the mean of three independent experiments. Statistical analysis was performed using one-way analysis of variance and the post-hoc Bonferroni test. *P<0.05 vs. untreated cells. LipPd1-3, lipoma phosphatase and tensin homolog-deficient 1-3.

Figure 3. Simvastatin treatment decreased AKT/mTOR activation following prolonged treatment. (A) LipPd1 cells were stimulated with 10 µM simvastatin in culture medium for 6, 12, 24 or 48 h. PTEN mRNA expression was quantified using reverse transcriptase polymerase chain reactions. Data were normalized to TBP and then compared with the expression level exhibited in the untreated controls. Relative expression of (B) phospho PTEN, (C) PTEN, (D) phospho AKT and (E) total AKT. (F) LipPd1 cells were stimulated with 10 µM simvastatin in culture medium for 48 h. Relative expression of (G) mTOR (Ser2448) and (H) 4E-BP1 (Thr37/46) were calculated. All data are presented as the mean ± standard error of the mean. Statistical analysis was performed using a Student’s t-test or one-way analysis of variance with a post hoc Bonferroni test. *P<0.05 vs. untreated cells. AKT, protein kinase B; mTOR, mammalian target of rapamycin; PTEN, phosphatase and tensin homolog; phospho, phosphorylated; LipPd1-3, lipoma PTEN-deficient 1-3; TBP, Tata box binding protein; Ser, serine; Thr, threonine; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; pAKT, phosphorylated AKT; 4E-BP1, 4E-binding protein-1; pmTOR, phosphorylated mTOR; p4E-BP1, phosphorylated 4E-BP1.
the present study assessed whether PPARγ knockdown would effect simvastatin-induced apoptosis. No significant differences in apoptosis induction or in the distribution of cells between early and late apoptotic phases were identified in PPARγ-knockdown cells compared with control-transfected cells following stimulation with simvastatin (Fig. 4D).

Discussion

At present, treatment options for patients with non-resectable PHTS-associated lipomatosis are limited. Sirolimus, an inhibitor of mTOR1, was successfully used to treat patients with other PHTS-associated complications (23-25). However, it was not effective at reducing lipoma growth in a patient with PHTS due to the heterozygous germ line deletion of PTEN (3). The aim of the present study was to test the effects of simvastatin on the growth of human lipoma cells derived from tumors with heterozygous mutations or deletions of PTEN. Simvastatin was selected for use as it has been demonstrated to exert anti-proliferative and growth-inhibitory actions on a number of cancer cell lines and tumor animal models (6,7,10,18,22,26-30). In accordance with these results, the present study demonstrated that simvastatin reduced the viability of PTEN mutant lipoma cells by inducing apoptosis in a time- and dose-dependent manner.

A potential mechanism of simvastatin action is the increase of PTEN protein levels and consequent suppression of AKT/mTOR signaling. This has been addressed by previous studies in various tissues, cancer cell lines and cancer xenograft animal models (8-10). In accordance with previous studies using tissues harvested from patients with PHTS (28,34), the results of the present study demonstrated that PTEN protein levels are reduced and AKT activation is increased in PTEN mutant lipoma cell cultures compared with PTEN wild-type cells. Furthermore, decreased PTEN mRNA levels were only identified in lipoma cells with a large heterozygous PTEN deletion (LipPd1 cells) and not in lipoma cells with heterozygous PTEN mutations (LipPd2 and LipPd3 cells). This contrast between normal mRNA expression and low protein levels may indicate the occurrence of a post-transcriptional event, such as increased protein degradation, due to mutations in PTEN.

Simvastatin treatment resulted in a transient upregulation of PTEN mRNA and protein levels in lipoma cells. In the present study, it was investigated by which mechanism simvastatin mediated this effect. The transcriptional regulator PPARγ has previously been reported to upregulate the transcription of PTEN and thereby influence AKT phosphorylation in non-malignant and cancer cells (10,19-22). The results of the present study demonstrate that PPARγ exhibits a similar expression pattern to PTEN following simvastatin stimulation of lipoma cells. However, the transient knockdown of PPARγ abrogated the increase in lipoma cell PTEN protein levels following simvastatin treatment.
Additionally, PPARγ knockdown had no effect on simvastatin-mediated induction of apoptosis. This is in contrast to previous studies, which demonstrated that the induction of apoptosis by PPARγ agonists occurs via the upregulation of PTEN (10,19,22,32-34).

Previous studies have reported various pathways by which simvastatin affects cell viability that are dependent on the inhibition of the cholesterol biosynthesis pathway, including the attenuation of NF-κB activation by a decrease in intracellular isoprenoid concentrations followed by impaired inner membrane attachment and Ras, Rac or Rho protein function (32,33). However, the lipoma cells used in the present study did not exhibit a decrease in NF-κB phosphorylation following incubation with simvastatin. The action of simvastatin in prostate cancer cells may be associated with decreasing cellular cholesterol levels, leading to altered membrane lipid raft structures, causing a reduction in AKT phosphorylation and thus resulting in apoptosis (38). This effect of simvastatin on caveolar raft structures has also been demonstrated in adipocytes (39). In accordance with this, the present study detected a decrease in AKT, mTOR and the mTOR target 4EBP-1 phosphorylation following prolonged treatment with simvastatin.

In conclusion, the results of the present study support the hypothesis that simvastatin treatment reduces the growth of lipoma cells and may be a promising candidate for the treatment of lipomatosis associated with PTEN haploinsufficiency. However, the effects of simvastatin are not mediated by PPARγ-facilitated upregulation of PTEN in lipoma cells. Further studies in suitable animal models are required to evaluate the use of simvastatin treatment in patients with lipomatosis associated with PTEN haploinsufficiency.

Acknowledgements

Not applicable.

Funding

The present study was supported by the Mitteldeutsche Kinderkrebsforschung (to FK), the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie agreement (grant no. 705869; to AG) and from Deutsche Forschungsgemeinschaft/Collaborative Research Centre SFB1052/B10 (to AG and WK).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

AG and NH conceived the study. AG, NH and FK designed the study and provided a major contribution to writing the manuscript. AG, NH, FK, TS and MP analysed data. WK interpreted patient data and discussed results. KL and AK provided expertise on adipocyte culture and knockdown experiments. FK, TS and SR performed experiments. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Ethical approval for these studies was obtained from the Ethics Committee of the University of Leipzig (ref. no. 425-12-171220; Leipzig, Germany). Written informed consent was provided by the parents of all patients enrolled in the present study.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References


